|
CHORDC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.40640000000103E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.176600E-04 |
| Normal-vs-Stage2 |
3.66990000000289E-05 |
| Normal-vs-Stage3 |
2.26640000000611E-06 |
| Normal-vs-Stage4 |
3.71499999995972E-06 |
| Stage1-vs-Stage2 |
7.513800E-02 |
| Stage1-vs-Stage3 |
8.976600E-04 |
| Stage1-vs-Stage4 |
8.335100E-03 |
| Stage2-vs-Stage3 |
5.311600E-01 |
| Stage2-vs-Stage4 |
5.144200E-01 |
| Stage3-vs-Stage4 |
8.748000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.17319999999255E-05 |
| Normal-vs-AfricanAmerican |
1.58047999999633E-05 |
| Normal-vs-Asian |
8.836200E-04 |
| Caucasian-vs-AfricanAmerican |
1.206390E-01 |
| Caucasian-vs-Asian |
4.095600E-01 |
| AfricanAmerican-vs-Asian |
8.118400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.57460000000432E-05 |
| Normal-vs-Female |
5.50449999999758E-05 |
| Male-vs-Female |
9.969400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.161000E-04 |
| Normal-vs-Age(41-60Yrs) |
2.40249999999831E-05 |
| Normal-vs-Age(61-80Yrs) |
1.00589999996181E-06 |
| Normal-vs-Age(81-100Yrs) |
2.341700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.027960E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.56510000000254E-05 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.063000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.855500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.025000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.627400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.059580E-03 |
| Classical-VS-Follicular |
3.751700E-02 |
| Classical-VS-Other |
4.310400E-01 |
| Classical-VS-Normal |
2.390700E-04 |
| Tall-VS-Follicular |
1.578580E-01 |
| Tall-VS-Other |
1.421840E-01 |
| Tall-VS-Normal |
9.65400000052519E-07 |
| Follicular-VS-Other |
1.737390E-01 |
| Follicular-VS-Normal |
2.17829999999974E-05 |
| Other-VS-Normal |
2.577000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.89803999999238E-05 |
| Normal-vs-N1 |
2.222300E-04 |
| N0-vs-N1 |
3.266400E-01 |
|
|
